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T3  antigen  is a  20-25  kD  complex on  human  T  cells  (1-3).  The  recently 
described T  cell receptors specific for antigen (5-9) are noncovalently linked to 
this antigen (6,  10). The role of T3 antigen in T  cell activation has been probed 
using  monoclonai  antibodies  (mAb) * directed  against  the  T3  antigen.  They 
induced  proliferation  of T  cells  (11,  12),  secretion  of lymphokines  (13-17), 
expression of interleukin  2  (IL-2) receptors (18,  19), and mobilization of Ca  ++ 
(20,  21).  The  majority  of these  effects appear  to be dependent  on  monocyte 
interaction with the  Fc portions of the antibodies  (22-29).  Recently, Jurkat,  a 
T3  ÷ human T  cell leukemia line, has been used as a model for T  cell activation. 
Anti-T3 antibodies were shown to deliver one of the two signals required for IL- 
2 gene activation, its synthesis, and secretion (30). Phorbol ester (TPA) rendered 
the other signal. 
Herein, three anti-T3 mAb of different isotypes (IgG1, IgG2a, and IgM) were 
generated  and  used  to  probe  activation  and  proliferation  of normal  human 
peripheral blood T  cells. One of these (IgM) was not mitogenic for T  cells in the 
presence of monocytes. All  three anti-T3  mAb,  in  the absence  of monocytes, 
and in collaboration with TPA, were able to induce isolated T  cells to express 
IL-2 receptors, to secrete IL-2, and to proliferate. 
Materials and Methods 
Monoclonal  Antibodies.  Three  mAb  against  T3  were  generated  and  named  T3-I 
(IgG2a), T3-II (IgG1), and 235 (IgM). TE, an mAb inhibiting T  cell rosette formation 
and  reacting with  a  55  kD  glycoprotein, was  an  IgG2a.  T3-I  and  T3-II  mAb  were 
produced in CF~ mice immunized with activated T  cells. TE and 235 were generated in 
BCsF1 mice, using thymocytes as the immunogen. Mice were immunized intraperitoneally 
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with  2  X  107 ceils,  with alum  as  an  adjuvant.  3  wk  later,  2  X  10  7 cells  in  phosphate 
buffered saline (PBS) were given intraperitoneally. Spleens were taken 3 d later. Fusion 
with  tumor  SP2/0  was  carried  out  as  described  (31).  Hybridoma supernatants  were 
screened against the immunizing cells  for their binding activities and their abilities to 
induce T  cell proliferation or block T  cell proliferation induced by allogeneic cells. The 
desired hybridomas were cloned twice on soft agar. Antibody subclass determination was 
made by enzyme-linked immunosorbent assay with subclass-specific  rabbit anti-mouse Ig 
antisera (Meloy Laboratories, Inc., Springfield VA) and alkaline phosphatase-linked goat 
anti-mouse Ig. mAb were purified from culture supernatants using goat anti-mouse Ig- 
Sepharose 4B column. Bound antibodies were eluted with glycine-HCl buffer, pH 2.9, 
dialyzed against PBS and sterilized by filtration. 
OKT3 and fluorescein isothiocyanate (FITC)-conjugated OKT3 were purchased from 
Ortho  Pharmaceuticals, Raritan  NJ.  Anti-Leu  1,  Leu 4, and  FITC-conjugated Leu 4 
mAb, and FITC-conjugated avidin were from Becton Dickinson and Co., Mountain View 
CA.  FITC-labeled, affinity-purified goat anti-mouse  IgM  (# heavy chain-specific) was 
purchased from Southern Biotechnology Associates,  Birmingham, AL. 
G3.5 (T12 equivalent) and 10.2 (Leu 1 equivalent) mAb (32) were generously provided 
by Dr. J.  A.  Hansen  (Fred Hutchinson  Cancer  Research  Center,  Seattle WA).  Anti- 
putative T cell receptor antibodies (anti-Ti) S160 (10) and C37 were generous gifts from 
Dr.  R.  Bigler (Rockefeller University, NY) and  Dr.  C.  Y.  Wang (The Sloan-Kettering 
Cancer Center, NY), respectively. 
Biotinylation  of  Purified AT-1 mAb.  AT-I, an mAb against IL-2 receptor, was produced 
as described previously (33).  Biotinylation of purified AT-1 was carried out according to 
a standard method. 0.5 ml of AT-1  (1  mg/ml) in 0.2 M Tris HCI, pH 8.1, was mixed 
quickly with 0.1 ml of 3.4 mg/ml biotin N-hydroxysuccinimide  ester (Calbiochem-Behring, 
San Diego CA) solution and stirred for 30 min at room temperature. The biotinylated 
AT-1 was extensively dialyzed against PBS. 
Cell Preparation.  Peripheral mononuclear cells (PMC) were isolated from buffy coats 
from normal donors or peripheral blood, using Ficoll-Hypaque density gradient centrif- 
ugation.  To  isolate  monocyte-free T  cells,  PMC  were  further  separated  by  Percoll 
continuous gradient  centrifugation,  followed by carbonyl-iron treatment,  nylon  wool 
column, and plastic adherence (34-36). Monocyte-free T cells were also obtained by sheep 
red blood cell (SRBC)  rosetting (37), carbonyl-iron treatment, nylon wool column, and 
plastic adherence. These T  cell preparations contained <0.1% monocyte, by nonspecific 
esterase staining. SRBC rosetting separation had no effect on the results, although T11 
antigen was found to be an alternative pathway of T  cell activation (38). 
Cells were suspended in complete media consisting of RPMI 1640 (Gibco, Grand Island 
NY) supplemented with  10%  heat-inactivated fetal calf serum (HyCione Laboratories, 
Logan UT), 2 mM L-glutamine, and 50 t~g/ml gentamicin (Gibco). 
Immunofluorescence  Studies.  Cells  were stained with mAb at 4°C  for 30  min.  After 
extensive washing,  the cells  were further incubated with  F1TC-conjugated goat anti- 
mouse F(ab)~ at 4 °C for 30 min. For the study on IL-2 receptor expression, biotinylated 
AT-1 was used as the first ligand, and FITC-conjugated avidin was used as the second 
ligand. After wash, the cells were analyzed with a Coulter Epics V flow cytometer (Coulter 
Electronics, Hialeah FL). Integrated fluorescence of the gated population was measured, 
and 10,000 cells were analyzed. 
Proliferation Assays.  PMC or monocyte-depleted T  cells (2  X  105 cells) in 200 #1 of 
complete medium were incubated in triplicate in flat-bottomed 96-well plates at 37 °C for 
3 d  in a  5%  COs atmosphere.  During the  last  8  h,  cells  were pulsed with 0.4 #Ci  of 
[~H]thymidine (specific activity 75 Ci/mmol; Amersham Corp., Arlington Heights IL) and 
incorporated radioactivity was determined as described (39). 
For proliferation assays, the following reagents were used: Phytohemagglutinin-P (PHA- 
P)  (Difco Laboratories,  Inc.,  Detroit  MI),  Concanavalin  A  (Con  A)  (Pharmacia  Fine 
Chemicals, Piscataway N  J), Pokeweed mitogen (PWM) (Gibco), tetanus toxoid (Common- 
wealth  Scientific Corp.  Alexandria  VA),  12-0-tetradecanoyl phorbol-13-acetate (TPA) HARA  AND  FU  643 
(Sigma Chemical Co., St. Louis MO), purified IL-1, IL-2, and recombinant IL-2 (Genzyme, 
Boston MA). 
Modulation Studies.  PMC (106 cells/ml) or cells of the HPB-ALL leukemic line (2.5 × 
10  ~ cells/mi) in complete medium were incubated with a saturating dose of mAb for 18 h 
at 37°C. Cells were washed three times, then stained as described above. 
IL-2 Activity Assay.  4  ×  10  "~ murine IL-2-dependent HT-2 cells  (a gift from Dr.  K. 
Himeno from Oklahoma Medical Research Foundation, Oklahoma City OK) in 100 #1 of 
complete media containing 2.5 ×  10  -~ M 2-mercaptoethanoi (2-ME) were incubated with 
100 #1 of culture supernatants of various dilutions, in triplicate, at 37°C for 24 h. Then, 
0.4 #Ci of [3H]thymidine was added, and incubation was continued for another 4 h. The 
incorporated radioactivity was assayed as described above. 
6  IL-2 Production.  T  cells (10  cells/ml) in complete medium were cultured for 12 h in 
the presence of various activators. Supernatants were collected by centrifugation, filtered, 
and assayed for IL-2 activity as described above. 
IL-1 Activity Assay.  Single-cell suspensions of mouse thymocytes (1.5 ×  10  7 cells/ml) in 
complete medium containing 2.5 x  10  -5 M 2-ME were cultured for 3 d with or without 
1 #g/ml PHA in the presence of  various dilutions oflL-1 (40). [3H]thymidine incorporation 
was determined after an 8 h pulse, as described above. 
Immunoprecipitation  and Autoradiography.  T  lymphocytes or HPB-ALL cells (2 ×  107) 
were labeled with ~25I (specific activity 15.8 mCi/#g of iodine; Amersham Corp.) by the 
lactoperoxidase technique,  or  with  [~SS]methionine  (specific activity  1,265  Ci/mmol; 
Amersham Corp.) in  methionine-free RPMI  1640 with dialyzed fetal calf serum. The 
labeled cells were solubilized in PBS containing 0.5% Nonidet P-40 (NP-40) and  1 mM 
phenylmethylsulfonyl fluoride. After centrifugation, supernatants were added to 30 #! of 
Sepharose 4B conjugated with goat anti-mouse Ig (5  mg/ml) that had been incubated 
with mAb. The mixture was incubated for 60 min at 4°C with constant mixing, and then 
washed three times with a buffer containing 10 mM Tris HCI, pH 7.8, and 0.6 M NaCi. 
Two additional washings with a buffer containing 10 mM Tris HCI, pH 8.8, 0.6 M NaCI, 
0.1% sodium dodecyl sulfate (SDS), and 0.05% NP-40 were carried out. The absorbed 
proteins  were  released  from  the  Sepharose  by boiling  for  3  min  in  a  sample  buffer 
containing 0.125 M Tris HCI, pH 6.8, 2% SDS,  5% 2-ME, and  10% glycerol, and were 
subjected to electrophoresis on  15% polyacrylamide gels in the presence of 0.1% SDS. 
Gets were stained,  destained, and dried.  Autoradiography was  carried out against  X- 
OMAT AR films at -70°C (41). 
Results 
Characterization  of Anti-T3  mAb.  We  found  two  mAb  to  be  mitogenic  for 
PMC. They were T3-I (IgG2a) and T3-II (IgG1). They precipitated a 22-24 kD 
molecule (Fig.  1, lanes 1 and 2) that had a similar electrophoretic mobility as the 
T3 antigen  precipitated by OKT3  and  Leu 4  in our gel system,  mAb  235, an 
IgM,  was  not  mitogenic.  It  blocked  T  cell  proliferation.  Despite  failure  to 
precipitate the T3 complex from either ~2~I surface-labeled or [35S]methionine 
metabolically-labeled T  cells,  we obtained data  to indicate that  it was  reactive 
with T3 antigen. 
In immunofluorescence assays, all three antibodies stained 85-95% of periph- 
eral blood T  cells, and ~60%  thymocytes. They failed to stain B cells, granulo- 
cytes, monocytes, erythrocytes, and platelets. 
The  relationship  between  our  anti-T3  antibodies  and  those  commercially 
available was investigated.  Unlabeled  mAb  Leu 4, T3-II, and  235 significantly 
blocked the staining of T  cells by OKT3-FITC (Fig. 2 A). T3-I was less effective. 
OKT3  and  T3-II  significantly blocked the  staining  of T  cells by Leu 4-FITC, 
while T3-I and 235 were less effective (Fig. 2 B). When FITC-labeled goat anti- 644  SYNERGY BETWEEN ANTI-T3 AND TPA IN HUMAN T  CELL ACTIVATION 
FIGURE  I.  hnmunoprecipitation of Ts-I and -11 antigens from  ~SI-labeled T  lymphocytes. 
lmmunoprecipitates by T3-1 (lane 1), T3-1I (lane 2), and control (lane 3) antibodies from 1~5I- 
labeled T  lymphocyte lysates were analyzed by SDS polyacrylamide gel electrophoresis under 
reducing conditions. The gel was dried and autoradiographed. 
mouse IgM and mAb 235 (IgM) were used, OKT3, Leu 4, and T3-II markedly 
blocked the staining by 235. T3-I blocked it very weakly (Fig. 2 C). These data 
indicate that OKT3, Leu 4, T3-II, and 235 react either with a similar antigenic 
determinant or determinants closely located on the T3 complex. T3-I appears 
to react with a distinct antigenic determinant. 
The reactivity of 235  against the T3  complex was further documented by 
comodulation experiments. In the first experiment, PMC were incubated with a 
saturating dose of anti-T3-II or 235 mAb at 37°C for 18 h. Cells were washed, 
stained, and analyzed. Modulation of the T3 complex by T3-II rendered T  cells 
nonreactive to  235  (Table  I).  Conversely, cells  modulated by  235  were  not 
stained by T3-II. Other T  cell antigens, such as T11 (55 kD) and Leu 1( 67 kD), 
were not affected by the modulation of the T3 complex. In a second experiment, 
we used two mAb (C37  and S160)  against putative T  cell receptors (Ti).  The 
first one (C37) was against a  80-90  kD heterodimer complex on the leukemia 
cell line HPB-ALL (Dr.  C.  Y.  Wang, personal communication), and S160  was 
against a  similar structure  on  leukemic cell  SU  (9).  These  two  Ti  structures HARA  AND  FU  645 
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FIGURE 2.  Flow-cytometer analysis of the interaction  between  mAb  235  and  anti-Ts.  (A) 
Inhibition of FITC-labeled OKT3 staining of PMC. PMC were incubated for 30 min at 4°C 
with an  unlabeled  mAb (OKT3,  Leu 4,  T3-I, T3-II, or 235) and  then washed  three times. 
Second incubation was carried out by adding a FITC-labeled OKT3 followed by analysis on a 
Coulter Epics  V  flow cytometer.  Control  indicates  the  staining  with  FITC-labeled OKT3 
alone.  (B)  Inhibition of FITC-labeled  Leu  4  staining of PMC.  Staining was  performed as 
described above, except that  FITC-labeled Leu 4  was used instead of FITC-labeled OKT3. 
Control indicates the staining with FITC-labeled Leu 4 alone. (C) Inhibition of the staining 
with 235 IgM and FITC-labeled goat anti-mouse lgM of PMC. First incubation was done as 
described  above.  Second  incubation  was  performed  by adding  235,  followed by  washing. 
Then, FITC-labeled goat anti-mouse IgM was added and analyzed on a Coulter Epics V flow 
cytometer. Control indicates the staining with OKT3, Leu 4, Ts-I, or T~-II and FITC-labeled 
goat anti-mouse IgM. 
TABLE  I 
Comodulation of 235 and T3 Antigens On Peripheral Mononuclear 
Cells 
Modulating  Stained cells 
antibody  235  T3-II (T3)  TE (Tl0  Leu 1 
% 
None  83.1  81.2  92.7  82.4 
235  1.7  4.0  93.4  84.2 
Ts-lI  0.9  1.7  92.0  81.3 
Peripheral mononuclear cells (108 cells/ml) were incubated with a saturat- 
ing dose of anti-Ts-lI or 235 mAb at 37°C for 18 h. Cells were washed, 
stained, and analyzed with a Coulter Epics V flow cytometer as described 
in Materials and Methods. 
comodulated  with  T3  antigens.  Table  II  details  the  experiment  involving  C37. 
Modulation  of HPB-ALL  cells by T3-II  or  235  rendered  the cells unreactive  to 
C37.  Modulation  of the Ti antigen  with C37  also modulated  the T3  complex,  as 
detected  by  T3-I,  T3-II,  or  235.  Similar  results  were  obtained  by  using  S160 
mAb  and  leukemic  cell SU. 
Inhibition of T Cell Proliferation by Nonmitogenic Anti-T3 mAb 235.  When  the 646  SYNERGY  BETWEEN ANTI-T3 AND TPA IN HUMAN T  CELL ACTIVATION 
TABLE  II 
Comodulation  of Ti and T3 Antigens on HPB-ALL. Evidence  That 
mAb 235 Is Directed Against the T3 Complex 
Modulating  Stained cells 
antibody  235  T~-I  T3-II  Ti (C37)  Leu 1 
None  93.8  94.3  95.2  93.3  91.8 
235  12.0  13.1  13.9  16.3  92.2 
T3-II  11.0  11.5  12.1  14.5  90.7 
Ti(C37)  19.7  18.7  21.6  9.7  89.6 
Modulation was carried out as described in Table I. 
TABLE  III 
Inhibition  of T Cell Proliferation  by mAb 235 
[SHlThymidine incorporation* 
IgM antibody  Tetanus 




0.05  41,842  107,537  29,211  35,323  9,271 
0.1  35,664 (14.2~  105,427  26,971  34,253  10,124 
0.5  24,637(40.7)  101,154  28,350  32,825  10,705 
1.0  8,192 (80.3)  100,908  20,018 (25.4)  9,615 (72.2)  3,813  (59.4) 
5.0  2,731  (93.4)  16,548 (84.4)  13,907  (48.2)  4,851  (86.0)  2,727 (71.0) 
10.0  1,517 (96.3)  9,437 (91.1)  12,661  (52.8)  2,344 (93.2)  1,983 (79.0) 
B-control 
ug/ml 
None  41,556  106,417  26,838  34,575  9,403 
0.05  42,714  102,968  26,631  33,441  9,421 
0.1  40,932  104,883  25,338  32,680  10,001 
0.5  39,688  104,892  28,539  33,707  9,563 
1.0  40,824  103,653  23,897  35,200  8,380 
5.0  40,032  103,407  26,033  34,901  10,195 
10.0  39,778  102,702  27,197  32,990  9,929 
Without  282  615  441  326  417 
mitogen 
* Peripheral mononuclear cells (2 ×  105) were stimulated with Con A (5 t~g/ml), PHA (10 ug/ml), 
PWM  (0.1%),  irradiated allogeneic cells (MLC,  2  X  105), or tetanus toxoid (20  eg/ml) in  the 
presence of various concentrations of mAb. [~H]Thymidine incorporation was measured after 3 d 
(for Con  A, PHA,  and  PWM) or 6  d  (for MLC and  tetanus toxoid) of incubation. Standard 
deviations of each value were within 10%. 
* Values in parentheses indicate percent inhibition. 
purified preparation  of IgM 235  was added at the start of cultures, it blocked T 
cell proliferation induced by mitogens (Con A, PHA, and PWM), allogeneic cells, 
and soluble antigen (tetanus toxoid) in a  dose-dependent  manner  (Table III). Of HARA  AND  FU  647 
the three mitogens employed in this investigation, mAb 235 was less effective in 
blocking  the  proliferation  induced  by PHA  or  PWM.  This  was  observed  in 
several experiments involving different individuals. To clarify which phase of T 
cell  activation  was affected,  235  was added  at  different  time  points  after  the 
initiation of mixed lymphocyte cultures (MLC). When 235 was added at the start 
of cultures,  it  blocked  the  proliferation  of allogeneic  T  cells  by  85%.  This 
inhibition decreased to 65% and 25% when the antibody was added 24 and 48 
h,  respectively, after the cultures were begun.  In contrast,  the addition of 235 
(0.05-50 #g/ml) to cultures of PHA-stimulated T  blasts did not interfere with 
proliferation induced by IL-2. 
T Cell Proliferation Induced by Anti-T3 mAb and TPA.  Although antibody 235 
was not mitogenic, and, in fact, inhibited T  cell proliferation induced by antigens 
and mitogens, it became mitogenic for PMC in the presence of TPA (Table IV, 
Exp. A).  For PMC, TPA was found to be quite mitogenic, in a dose-dependent 
manner.  At all doses, antibody 235, as well as the other two mitogenic anti-T3 
mAb showed a synergistic effect with TPA in the induction of T cell proliferation. 
Antibody T3-II  is an  IgG1.  We confirmed  reports (23,  28) that  there  were 
nonresponders in the control population. In three nonresponders, T3-II became 
mitogenic in the presence of TPA, and the degree of proliferation  was similar 
to that induced by T3-I (IgG2a). 
We looked at the role of monocytes in this system. Two methods were used to 
deplete monocytes from T  cell preparations.  In the absence of monocytes, T3-I 
TABLE IV 
Effect of Various Concentrations of TPA on the Mitogenic Activity of mAb 
mAb (1 ug/ml) against: 
TPA concentration (ng/ml) 
0  0.3  1.0  3.0 
cpm 
A.  Peripheral mononuclear cells 
Medium  625  1,496  17,572  47,776 
Control IgM  632  1,537  17,842  45,005 
235 lgM  452  12,866  91,611  84,577 
T3-1  58,033  71,986  96,711  91,908 
T3-11  55,381  66,734  90,891  92,973 
B.  Monocyte-depleted T  cells 
Medium  194  540  2, t 32  6,952 
235 lgM  188  16,090  66,340  52,983 
Ta-I  230  22,151  53,671  47,912 
Trll  226  12,356  56,525  43,606 
10.2 (Leu  1)  235  916  3,044  6,676 
TE (TI 1)  255  535  1,189  4,919 
G3.5 (TI 2)  150  988  1,945  6,606 
2 X  105 cells were incubated with  1 ug/ml mAb in the presence of various concentrations of TPA. 
[3H]Thymidine uptake was measured after 3 d. Standard deviations of each mean value were within 
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and T3-I1 were no longer mitogenic (Table IV, Exp. B). TPA was also much less 
mitogenic.  In  this  system,  all  three anti-T3  mAb  (1  ug/ml)  showed  a  similar 
potency in the induction of T  cell proliferation in the presence of TPA. Other 
pan-T mAb, such as 10.2 (Leu 1), TE (TII), and G3.5 (T12) showed no mitogenic 
effect in the presence of TPA, with or without monocytes. 
The magnitude of the responses of isolated T  cells to anti-T3 in the presence 
of TPA  was  similar  to  that  induced  by  T3-I  and  T3-II  in  the  presence  of 
monocytes. It appears that more vigorous proliferation was observed when anti- 
T3 and TPA were added to unseparated mononuclear cells (Table IV). This was 
observed in  three separate  experiments.  Although  T  cell preparations  isolated 
by rosetting with SRBC were utilized in these experiments, comparable results 
were obtained  with  monocyte-depleted T  cell preparations  isolated by Percoll 
gradient centrifugation and nylon wool column purification. 
With  a  nonmitogenic dose of TPA  (0.3  ng/ml),  increasing doses of anti-T3 
induced more proliferation (Table V). mAb 235 was less potent than T3-I and 
T3-II.  The  pentameric  nature  of  IgM  may  account  for  this  discrepancy  in 
potency. 
IL-2 Receptor Expression and IL-2 Production.  T  cell activation with anti-T3 
mAb  in  the  presence  of TPA  was  associated  with  a  marked  increase  in  IL-2 
receptor expression as detectable by our mAb  AT-1.  (Table VI).  Because the 
cells were cultured in the presence of mouse mAb, biotinylated AT-1  was used 
with avidin-FITC. With anti-T3 alone,  10% of the T  cells weakly expressed IL- 
2 receptors at all time points studied. Although TPA did not induce a high level 
of proliferation, a significant number of T  cells were positive for IL-2 receptors. 
However, the intensity of fluorescence was quite weak (Fig.  3). In the presence 
of anti-T3 mAb and TPA, 80% of the T  cells were positive by 12 h, and ~90% 
became strongly positive by 60 h  (Table VI and Fig. 3). This was observed with 
all three anti-T3 mAb. 
IL-2 production by T  cells stimulated by anti-T3 in the presence of TPA was 
detected 12 h after the initiation of cultures (Table VII). Significant proliferation 
by HT-2 cells was detected even when the supernatants were diluted to 1:20 and 
1:60. Supernatants from cultures with either anti-T3 or TPA alone did not show 
IL-2 activities.  As an additional  control, addition  of anti-T3  to collected TPA 
supernatant did not support the growth of HT-2 cells. 
IL-1  and IL-2 Did Not Restore T Cell Responsiveness to Anti-T3 in the Absence of 
TABLE  V 
Lymphocyte Proliferation by Various Concentrations of mAb in Presence of TPA 
mAb 
Antibody concentration (ng/ml) 
0  1  10  100  100 
cpm 
235 (lgM)  289  471  603  12,478  25,269 
Trl (lgG2a)  177  7,330  25,188  31,472  29,540 
T~-II (IgG1)  227  200  10,191  32,743  31,508 
Monocyte-depleted T cells (2 ×  10  s cells), prepared  as described in Materials and Methods, were 
cultured in the presence of various concentrations of mAb and 0.3 ng/ml TPA for 3 d. Standard 
deviations of each mean value were within 15%. HARA  AND  FU  649 
TABLE  VI 
Time Course of Expression of lL-2 Receptors on Monocyte-depleted 
T Cells 
Culture condition 
IL-2 receptor-positive cells  [SH]Thymi- 
dine incor- 
12 h  36 h  60 h  poration 
%  cpm 
235 + TPA  80.6  89.2  89.2  73,539 
T3-I + TPA  80.2  89.4  88.4  73,194 
T3-1I + TPA  79.6  89.1  90.9  72,548 
235 (1 ug/ml)  2.6  3.5  3.9  147 
T3-I (1 ug/ml)  8.2  8.9  9.7  116 
T3-II (1 ug/ml)  8.7  9.3  9.9  116 
TPA (0.6 ng/ml)  42.7  66.6  68.6  1,306 
Medium  2.8  3.6  4.0  173 
Monocyte-depleted T  cells (106  cells/ml) were  stimulated as described 
above. The percentages of IL-2 receptor-positive cells were determined 
by biotinylated AT-1 (anti-IL-2 receptor) and avidin-FITC at the indi- 
cated times. 104 cells were analyzed with a Coulter Epics V flow cytometer 
as described in Materials and Methods. [SH]Thymidine incorporation was 
determined after 3 d  in culture. These data are representative of three 
independent experiments. 
Ilt~  ~  I 2h 
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Fluorescence  Intensity 
FtCUR~ 3.  Flow-cytometer analysis of the expression of IL-2 receptors on T cells. Monocyte- 
depleted T  cells were incubated with medium or 235 (1 ~g/ml) alone (2), TPA (0.6 ng/ml) 
alone (3), or TPA and 235 (4).  IL-2 receptor-positive cells were determined by biotinylated 
AT-I  and avidin-FITC, and analyzed with a  flow  cytometer as described in Table VI. (1) 
indicates the staining with nonbiotinylated AT-1 and avidin-FITC. 
Monocytes.  IL-1  and  IL-2  were  added  to  monocyte-depleted  T  cell cultures  to 
determine  if they could restore  their  responsiveness to anti-T3  mAb.  As shown 
in  Table  VIII,  IL-1  did  not  restore  T  cell  responsiveness  to  anti-T3  in  the 
absence  of  monocytes.  The  IL-1  preparation  was  shown  to  be  active  by  its 
augmentation  of  PHA  stimulation  of mouse  thymocytes.  In  this  assay,  mouse 650  SYNERGY BETWEEN ANTI-T3 AND TPA IN HUMAN T  CELL ACTIVATION 
TABLE  VII 
IL-2 Production by Monocyte-depleted T Cells Stimulated by Anti-T3 
mAb and TPA 
Culture condition 
[3H]Thymidine incorporation at final 
dilutions of: 
1:2  1:6  1:20  1:60 
cpm 
235 +  TPA  9,714  5,639  2,815  1,477 
T3-I +  TPA  10,306  6,945  4,579  2,445 
T3-II +  TPA  10,796  6,952  4,210  2,165 
235 (1 ~g/ml)  1,479  1,203  1,092  883 
T3-I (1 ug/ml)  1,683  1,359  1,329  819 
T3-II (1 ~g/ml)  1,654  1,433  1,444  858 
TPA (0.6 ng/ml)  1,564  1,405  1,219  837 
Medium  1,635  1,450  1,446  1,107 
Monocyte-depleted T  cells (106 cells/ml) were cultured in the presence of 
stimulator(s). After 12 h, supernatants were harvested, and their ability to 
stimulate [SH]thymidine incorporation into murine IL-2-dependent HT-2 
cells was determined.  The standard deviation of each value was within 
15%. Three independent experiments showed similar results. 
TABLE  VIII 
Effects of lL-1 and IL-2 on T Cells in Presence of Anti-T3 
Interleukin  Medium 
mAb (1 #g/ml) 
235  T3-I  T3-II 
U/ml  cpm 
IL-1 
0  173  331  538  544 
2.5  279  173  778  803 
5  262  263  665  699 
10  165  310  907  703 
IL-2 
0  294  174  370  230 
125  254  1,329  1,905  1,527 
250  291  2,715  3,272  2,852 
500  428  3,673  5,739  4,455 
IL-2  (recombi- 
nant) 
125  440  3,176  4,716  3,276 
250  385  4,376  7,331  5,469 
500  917  5,065  8,237  6,374 
Monocyte-depleted T  cells (2  ×  105 cells) were cultured  for 3  d  in the 
presence of various concentrations of IL-1 or IL-2 with or without anti- 
T3 mAb (1 t~g/ml). Standard deviations of each mean value were within 
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thymocytes incorporated 796 cpm of [3H]thymidine in the presence of PHA (1 
#g/ml). With 2.5 U/ml of IL-1 added, 15,630 cpm was taken up. 
Both purified and recombinant IL-2 augmented anti-T3 mAb in the induction 
of T  cell proliferation. However, the effect was quite small in comparison to that 
of TPA. 
Discussion 
We raised three mAb (T3-I, T3-II, and 235) and used them to probe the role 
of the T3 complex in human T  cell activation. T3-I (IgG2a) and T3-II (IgG1) 
precipitated a T3 complex and behaved similarly to OKT3 (IgG2a) and Leu 4 
(IgG 1), respectively, in terms of their mitogenicity for T  cells in the presence of 
monocytes. 235, an IgM mAb stained T  cells, blocked the staining of T  cells by 
FITC-OKT3 or FITC-Leu 4, and induced the modulation of the T3/Ti complex. 
Modulation  of the  T3/Ti  complex  by  anti-T  cell  idiotypic  antibodies  also 
rendered the T cells unreactive to 235. Although repeated attempts to precipitate 
the T3 complex with 235  were unsuccessful, the accumulated evidence led to 
the conclusion that 235 was reactive with the T3 complex. 
235 by itself was not mitogenic for T  cells in the presence of monocytes. This 
is similar to other anti-T3 antibodies of IgM isotype (29, 42).  In addition, 235 
IgM was an effective inhibitor of T  cell proliferation (Table III). Recently, Leu 
4  (IgG1) has been shown to inhibit T  cell mitogenesis in individuals whose T 
cells were nonresponsive to Leu 4 in the presence of autologous monocytes (43). 
That nonmitogenic anti-T3 mAb can block antigen- and mitogen-induced T  cell 
proliferation  underscores  the  central  role  of the  T3/Ti  complex  in  T  cell 
activation. 
Despite its inhibitory effect, 235 in the presence of TPA was mitogenic for T 
cells. T3-I and T3-II were also mitogenic to monocyte-depleted T  cells in the 
presence of TPA. This indicates that 235, as well as T3-I and T3-II, was capable 
of delivering an inductive signal in the absence of monocytes. This is consistent 
with the finding that anti-T3  antibodies induce Ca  ++ influx in the absence of 
monocytes (20,  21).  Preliminary  experiments  using  3,3'-dipentyloxacarbocy- 
anine iodide as a  probe  (44)  showed that all  three anti-T3  mAb used in  this 
investigation  induced  membrane depolarization  of T  cells  in  the  absence  of 
monocytes. Our T  cell preparations contained <0.1%  monocytes, as measured 
by nonspecific esterase staining, and were no longer responsive to T3-I and T3- 
II. Furthermore, nonmitogenic 235  IgM, which appeared to have little interac- 
tion with monocytes, behaved similarly to T3-I and T3-II  in T  cell activation 
and proliferation in the presence of TPA. Thus, the T  cell mitogenic effect of 
anti-T3 plus TPA is independent of monocytes. The effect was preceded by the 
induction of IL-2 receptors and by IL-2 secretion. (Tables VI and VII). These: 
data  suggest  that  two  signals  are  necessary for normal  T  cell activation  and 
proliferation. This is analogous to the two-signal model (30) of IL-2 induction 
and secretion in Jurkat cells, a T  leukemia line. 
In a  recent study by Clement (42), a  direct anti-T3-mediated interaction of 
the  T3  molecules  with  monocyte  membrane  appeared  to  be  necessary  for 652  SYNERGY BETWEEN ANTI-T3 AND TPA IN HUMAN T  CELL ACTIVATION 
mitogenesis. In his system, anti-T3 (IgG1) was used to deliver an inductive signal 
to  T  cells  from  nonresponsive  individuals.  An  attempt  to  generate  a  second 
signal was carried out by incubating anti-T3  (IgG1)-coated T  cells with mono- 
cytes in the presence of an anti-p67 (a Leu 1-equivalent IgG2a). This interaction 
did not induce T  cell proliferation.  It is likely that close interaction  between T 
cells and  monocytes, mediated by anti-T3,  activates a  structure on or near  the 
T3 complex. TPA may act on this structure,  and thus it can substitute for the 
required  monocyte function. At any rate,  these results further support the use 
of anti-T3-induced  T  cell proliferation as a good model for antigen-induced  T 
cell proliferation  that  also requires close contact between T  cells and antigen- 
presenting cells (45). 
We, as well as others (46, 47) clearly establish that TPA can deliver a second 
signal in normal  T  cell activation; the first signal being rendered by anti-T3,  or 
T  cell mitogens.  TPA has been shown to have diverse cellular effects (48, 49). 
We do not yet know which of these effects is responsible for the results observed 
in our system. Note that TPA, by itself, could induce a low level of IL-2 receptor 
expression  without  inducing  IL-2  production  in  monocyte-depleted  T  cells. 
These results indicate the complexity in the events leading to T cell proliferation. 
Our attempts to substitute IL-1 or IL-2 for TPA were not successful. IL-1 had 
no effect on T  cell proliferation  when  it was added,  together with anti-T3,  to 
monocyte-depleted T  cells.  IL-2 did collaborate with anti-T3  to induce T  cell 
proliferation.  However,  this  effect was quite  small.  Under  this  condition,  the 
expression  of  IL-2  receptors  was  only  slightly  enhanced.  Furthermore,  the 
addition of 1%  of monocytes to these cultures markedly enhanced  both T  cell 
proliferation  and  IL-2 receptor expression (T.  Hara and  S.  M.  Fu, manuscript 
in preparation).  These results are in agreement with those reported recently by 
Welte et al. (50). While our results did not support the assignment of a primary 
role  of IL-1  and  IL-2  in  anti-T3-induced  mitogenesis,  the  possibility  that  a 
higher  concentration  of these  interleukins,  achievable  in  the  case  of cell-cell 
contact, might play such a role, cannot be discarded. Our results do not rule out 
the possibility that other monokines yet to be identified may also be involved. 
Our experimental approach has also been used to probe action by other anti- 
T  cell antibodies.  Anti-p55  (T11,  SRBC receptor),  anti-p67  (Leu  1), and anti- 
p100 (T12) antibodies were found not to be mitogenic for T cells in the presence 
of TPA.  Certain  anti-T11  antibodies  in  combination  have  been  shown  to  be 
mitogenic,  and  T11  has been postulated to be an  alternative  T  cell activation 
pathway (38). The lack of responsiveness ofT cells to anti-T11  plus TPA further 
suggests that  the T11  activation pathway differs from that involving the T3/Ti 
complex.  Of  four  anti-T  cell-subset  antibodies  (anti-p55  IT4],  anti-p32-45 
[T8], anti-p40 [3All, and anti-p44 [9.3]), only 9.3 induced T  cells to proliferate 
in collaboration with TPA (T.  Hara, S. M.  Fu, and J. A. Hansen; submitted for 
publication.)  It  is  of interest  to  note  that  the  9.3  antigen  is a  disulfide-linked 
dimer  of a  44  kD  polypeptide.  The  activation  of T  cells  by 9.3  and  TPA  is 
accompanied by IL-2 secretion and  IL-2 receptor expression in a  manner  very HARA  AND  FU  653 
similar to that seen with anti-T3 and TPA. Thus, our approach has proven useful 
for probing T  cell-antigen function. 
Summary 
Three monoclonal antibodies (mAb), of IgG 1, IgG2a, and IgM isotypes, raised 
against the T3  complex,  were  used to probe  the activation of human T  cells. 
The  IgM  antibody 235  was  not mitogenic  for peripheral  blood  mononuclear 
cells (PMC).  It efficiently blocked the proliferation of PMC induced by T  cell 
mitogens,  alloantigens,  and  soluble  antigens.  The  other  two  antibodies  were 
mitogenic, and behaved similarly to  Leu 4  and OKT3,  respectively.  In T  cell 
preparations with <0.1% monocytes (as assayed by nonspecific esterase staining), 
all three  mAb were  not mitogenic. They failed to induce either interleukin 2 
(IL-2) receptor expression or IL-2 secretion. Addition of IL-1 failed to collabo- 
rate with anti-T3 mAb to induce these T  cells to proliferate, but IL-2 enhanced 
T  cell proliferation slightly. Monocyte-depleted T  cells, however, proliferated in 
response to all three anti-T3 mAb, when TPA was added, in a dose-dependent 
manner.  TPA  induced  a  low  level  of IL-2  receptor  expression  in  monocyte- 
depleted T  cells, without inducing IL-2 secretion. Anti-T3 plus TPA induced a 
marked enhancement in both quantity and intensity of IL-2 receptor expression. 
IL-2 secretion  was also  detected.  These results indicate that anti-T3  IgM can 
deliver an inductive signal despite its blockage of T  cell proliferation, and that 
two signals are necessary and perhaps sufficient to induce human T  cell activation 
and proliferation. 
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